---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076617"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:45:06.589676+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics reports Q4 net loss $0.32/share; cash $554.5M; zovegalisib milestones in 2026

## Summary
- Q4 2025 net loss $54.9M ($0.32/share) vs $76.0M ($0.45) in Q4 2024; full year net loss $276.5M ($1.61/share).
- Cash, cash equivalents and investments $554.5M at Dec 31 2025, down from $781.3M; runway into 2029.
- Revenue $7.0M in Q4 2025 (Elevar license) vs $0 in Q4 2024; full year revenue $15.4M.
- Zovegalisib Phase 1/2 breast cancer data at ESMO TAT March 16 in 57 patients at Phase 3 dose.
- Initial vascular anomalies data expected 1H 2026; pediatric cohort in ReInspire trial opened early.

## SEC filing metadata
- accession: 0001193125-26-076617
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000119312526076617/0001193125-26-076617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000119312526076617/rlay-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076617
- JSON: https://secwatch.observer/filing/0001193125-26-076617.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.